Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | MMP1 | P03956 | 4/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.55 |
| ▸ | MMP9 | P14780 | 4/20 | 0.55 |
| ▸ | MMP8 | P22894 | 4/20 | 0.55 |
| ▸ | MMP13 | P45452 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767644 | 0.83 | PTGES2 (0.54) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6928314 | 0.82 | ALDH1A1 (0.56) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL5806023 | 0.80 | ALDH1A1 (0.55) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL2371935 | 0.78 | GAA (0.58) | CA1CA2ALDH1A1GAATSHR | |
| SCHEMBL9598797 | 0.78 | ALDH1A1 (0.53) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL23747022 | 0.78 | ALDH1A1 (0.53) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| Potassium SCHEMBL9789251 | 0.78 | ALDH1A1 (0.53) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL420397 | 0.78 | GAA (0.53) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL2371933 | 0.78 | ALDH1A1 (0.53) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL2244891 | 0.78 | ALDH1A1 (0.53) | ALDH1A1GAATSHRHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | claimed |
| US-20160002156-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2016-01-07 | — | — | US | claimed |
| US-RE45314-E1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-12-30 | — | — | US | claimed |
| CN-101472576-B | N-Hydroxysulfonamide Derivatives as Physiologically Valuable Nitroxyl Donors | UNIV JOHNS HOPKINS MED | 2013-04-17 | — | — | CN | claimed |
| EP-2504003-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | Cardioxyl Pharmaceuticals Inc. (US) | 2012-10-03 | — | — | EP | claimed |
| US-20110306614-A1 | N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-12-15 | — | — | US | claimed |
| US-8030356-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | claimed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | claimed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| CN-101472576-A | N-hydroxysulfonamide derivatives as novel physiologically valuable nitroxyl donors | UNIV JOHNS HOPKINS (US) | 2009-07-01 | — | — | CN | claimed |
| EP-1998761-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | Johns Hopkins University School of Medicine (US) | 2008-12-10 | — | — | EP | claimed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | claimed |
| WO-2007109175-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-09-27 | — | — | WO | claimed |
| US-11306056-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| CN-109438298-B | N-hydroxysulfonamide derivatives as physiologically valuable nitroxyl donors | 约翰斯霍普金斯大学 | 2021-10-08 | — | — | CN | disclosed |
| WO-2007109175-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109175-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007002444-A1 | THIOL-SENSITIVE POSITIVE INOTROPES | JOHNS HOPKINS UNIVERSITY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306614-A1 | N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors | TNNI3, TNNC1, NME4 | CA1 2599/4885CA2 1456/4885MMP1 2327/4885 |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | CA1 3786/4885CA2 459/4885MMP1 1456/4885 |
| US-20160002156-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | CA1 2599/4885CA2 1456/4885MMP1 2327/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | CA1 3870/4885CA2 747/4885MMP1 1165/4885 |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, NME4 | CA1 2599/4885CA2 1456/4885MMP1 2327/4885 |
| US-11306056-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, TNNT2 | CA1 2645/4885CA2 1468/4885MMP1 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.